Novo Nordisk has reduced the price of Wegovy to $499 per month for patients without insurance coverage, aiming to improve accessibility after the end of the semaglutide shortage indicated by the FDA. The move mirrors similar initiatives by Eli Lilly. Experts suggest the price is still high, maintaining pressure on Novo Nordisk regarding drug affordability.